Key facts
- It has raised $20.0M; the latest was Early Stage VC ($20.0M) in Feb 2026.
- Notable investors include IAG Capital Partners, Hatteras Venture Partners, Arboretum Ventures, Laerdal Million Lives Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Pharaoh Neuro
- ·The full record, as it builds
Funding rounds
No funding rounds for Pharaoh Neuro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pharaoh Neuro
Developer of a medical device company intended for cerebrospinal fluid (CSF) management. The company's investigational neurapheresisTM CSF management system allows precision management of CSF to restore equilibrium and protect brain health, enabling neurocritical patients to maintain intracranial pressure, clear metabolic waste, and deliver essential nutrients.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2024
- Employees
- 4
- Website
- pharaohneuro.com/
- Ownership
- Privately Held (backing)
Pharaoh Neuro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pharaoh Neuro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pharaoh Neuro in its N-PORT filings yet. We sweep new filings monthly.